There are 2137 resources available
300P - Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
Presenter: Emma Zattarin
Session: E-Poster Display
Resources:
Abstract
301P - Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1
Presenter: Yen-Shen Lu
Session: E-Poster Display
Resources:
Abstract
302P - Utility of lymphocyte-monocyte ratio (LMr) for predicting progression free survival (PFS) in patients with HR+/HER2- metastatic breast cancer (MBC) treated with palbocilcib + fulvestrant as first-line therapy
Presenter: Lucrezia Raimondi
Session: E-Poster Display
Resources:
Abstract
303P - Use of CA 15.3 for the detection of secondary metastatic breast cancer
Presenter: Lore De Cock
Session: E-Poster Display
Resources:
Abstract
305P - Patterns of acquired mutations in estrogen receptor-positive metastatic breast cancer (MBC) patients identified by comprehensive genomic profiling (CGP)
Presenter: Kimberly McGregor
Session: E-Poster Display
Resources:
Abstract
304P - ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial
Presenter: Jean-Sebastien Frenel
Session: E-Poster Display
Resources:
Abstract
306P - Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program
Presenter: Amélie Francois
Session: E-Poster Display
Resources:
Abstract
307P - Real-world evidence of CDK4/6 Inhibitor combination effects on assessing outcome with different sequence of treatment among adult patients with HR + and HER2 - metastatic breast cancer
Presenter: Silvia Comis
Session: E-Poster Display
Resources:
Abstract
308P - Real-world outcomes among HER2+ metastatic breast cancer patients with brain metastases
Presenter: Nicolas Lindegger
Session: E-Poster Display
Resources:
Abstract
309P - Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC)
Presenter: Stuart Turner
Session: E-Poster Display
Resources:
Abstract